Clinical trials
Positron Emission Tomography clinical trials
Below are recruiting positron emission tomography clinical trials, each written for real people, not researchers. We’re tracking 344 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06447103RecruitingPhase 2
New scan to find kidney cancer after surgery
This trial tests a special PET scan to see if it can better find leftover kidney cancer after surgery compared to a standard CT scan. You may qualify if you had kidney cancer surgery within the last 4-16 weeks and are at high risk of the cancer coming back.
Los Angeles, CaliforniaAges 18 years+ - NCT06357676RecruitingPhase 1/Phase 2
Glofitamab, Ibrutinib and Obinutuzumab for Untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
Portland, OregonAges 18 years+ - NCT06337318RecruitingPhase 3
Comparing two drugs for low-tumor burden follicular lymphoma
This trial compares a standard drug called rituximab to a newer medicine called mosunetuzumab for people with a slow-growing type of lymphoma that is not causing many symptoms. The goal is to see if mosunetuzumab works better and has fewer side effects.
Birmingham, AlabamaAges 18 years+ - NCT06320405RecruitingPhase 1/Phase 2
Combination therapy for advanced solid tumors
This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.
Portland, OregonAges 18 years+ - NCT06288113RecruitingPhase 2
Re-treatment with 177Lu-PSMA-617 for prostate cancer
This trial tests if a second round of a targeted radiation therapy (177Lu-PSMA-617) can help men whose prostate cancer has returned after a successful first treatment. It is for men whose cancer has stopped responding to hormone therapy and chemotherapy, and whose PSA levels have risen again after a prior good response to this drug.
Los Angeles, CaliforniaAges Any age - NCT06244004RecruitingPhase 2
PET-guided radiation for metastatic hormone-sensitive prostate cancer
This trial tests whether using a special PET scan (FDG-PET) to find and treat only the spots where cancer has spread with targeted radiation can help men with prostate cancer that has spread but still responds to hormone therapy. It compares standard treatment alone to standard treatment plus this targeted radiation.
Chicago, IllinoisAges 18 years+ - NCT06209619RecruitingPhase 1
Study of CC-99282 plus rituximab after CAR-T for lymphoma
This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.
Columbus, OhioAges 18 years+ - NCT06216249RecruitingPhase 2
Flexible dosing of Lu-PSMA for advanced prostate cancer
This trial tests a flexible dosing schedule of a targeted radiation drug (Lu-PSMA) for men with metastatic prostate cancer that has stopped responding to hormone therapy and chemotherapy. It aims to see if adjusting the treatment schedule can improve outcomes while reducing side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Birmingham, AlabamaAges Up to 30 years - NCT05516732Recruiting
Testing serotonin activity in the brain in people with Parkinson’s
This study uses special scans to measure how serotonin is released in parts of the brain involved in movement in Parkinson’s disease. It may help researchers understand disease changes and the role of serotonin systems in movement problems.
Exeter, DevonAges 25–85 - NCT05516719Recruiting
Study tracking I2BS in Parkinson’s over time
This study follows people with Parkinson’s to see how “I2BS” changes over time using special brain scans and other tests. It may help researchers better understand Parkinson’s and improve how it’s measured in future trials.
Exeter, DevonAges 25 years+ - NCT06145633RecruitingPhase 2
Vorinostat and 177Lu-PSMA-617 for PSMA-Low prostate cancer
This trial tests two drugs: vorinostat (a pill that may make cancer cells easier to target) and 177Lu-PSMA-617 (a radioactive drug that seeks out prostate cancer cells). It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and shows low levels of PSMA on a PET scan.
Seattle, WashingtonAges Any age - NCT06113510Recruiting
Clot imaging for heart attacks with clear arteries
This study uses a special type of MRI to look for tiny blood clots in the heart arteries that may have caused a heart attack even when standard tests show no major blockages. It aims to better understand the cause of heart attacks in people with this uncommon pattern.
EdinburghAges 18 years+ - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Tucson, ArizonaAges 18 years+ - NCT05558904RecruitingPhase 1/Phase 2
PET/CT scan to help find early lung cancer
This trial tests a special PET/CT scan to spot early lung cancer by finding specific body processes linked to cancer. It compares scan results in people with lung nodules that are either cancer (lung adenocarcinoma) or likely benign.
Los Angeles, CaliforniaAges 18 years+ - NCT06058663RecruitingPhase 1
Radiation and immunotherapy for advanced bile duct cancer
This trial tests combining a targeted radiation treatment (radioembolization) with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced intrahepatic cholangiocarcinoma that cannot be removed by surgery. It aims to shrink tumors and control cancer spread to lymph nodes or one other organ.
Jacksonville, FloridaAges 18 years+ - NCT06039371RecruitingPhase 2
High dose testosterone during chemo for advanced prostate cancer
This trial tests if adding high doses of testosterone to standard chemotherapy (etoposide and carboplatin) can make the chemo work better in men whose prostate cancer has stopped responding to other treatments. It aims to see if this approach can shrink tumors or slow cancer growth.
Seattle, WashingtonAges 18 years+ - NCT06048250RecruitingPhase 1
Mezigdomide after Abecma for multiple myeloma
This trial tests a new drug called mezigdomide (CC-92480) for people with multiple myeloma who have already received the CAR T-cell therapy Abecma. The goal is to see if mezigdomide can help keep the cancer under control after Abecma.
Duarte, CaliforniaAges 18 years+ - NCT06015880RecruitingPhase 1
Combination drug therapy for relapsed or resistant large B-cell lymphoma
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT05994014Recruiting
Comparing two heart scans for artery blockages
This study compares two types of heart scans to see which one better finds blockages in the arteries of people with chest discomfort or shortness of breath when active. You will have both a special CT scan and a PET/CT scan to check the health of your heart arteries.
Baltimore, MarylandAges 18 years+ - NCT05976763RecruitingPhase 3
Testing continuous vs. intermittent zanubrutinib for older adults with mantle cell lymphoma
This trial tests whether taking the targeted drug zanubrutinib continuously is better than taking it on a schedule with breaks for older adults with untreated mantle cell lymphoma. The goal is to find a treatment that works while reducing side effects.
Little Rock, ArkansasAges 60 years+ - NCT05948657Recruiting
PSMA PET-CT scan for men on prostate cancer surveillance
This study checks whether a special prostate scan called PSMA PET-CT (along with standard monitoring scans) can help guide care while you are on “active surveillance” instead of immediate treatment. It may help doctors track low-risk prostate cancer changes more accurately over time.
Los Angeles, CaliforniaAges 18 years+ - NCT05886036RecruitingPhase 2
Comparing rituximab vs mosunetuzumab for NLPHL
This trial compares two immunotherapy drugs, rituximab and mosunetuzumab, to see which works better for people with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) who need treatment. It's for both newly diagnosed and previously treated patients.
Duarte, CaliforniaAges 18 years+ - NCT05892393RecruitingPhase 1
Scan test to find CD46-positive multiple myeloma lesions
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
San Francisco, CaliforniaAges 18 years+
Hear when a new Positron Emission Tomography trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for positron emission tomography?
- Yes. Clin2 currently lists 344 recruiting positron emission tomography studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a positron emission tomography trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a positron emission tomography trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.